Disparate Effects of Obesity and Left Ventricular Geometry on Mortality in 8088 Elderly Patients with Preserved Systolic Function

2009 ◽  
Vol 121 (3) ◽  
pp. 119-125 ◽  
Author(s):  
Carl J. Lavie ◽  
Richard V. Milani ◽  
Dharmendrakumar Patel ◽  
Surya M. Artham ◽  
Hector O. Ventura
Keyword(s):  
Elderly Patients ◽  
Systolic Function ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Geometry

scholarly journals Blood Pressure, Left Ventricular Geometry, and Systolic Function in Children Exposed to Inorganic Arsenic

2015 ◽  
Vol 123 (6) ◽  
pp. 629-635 ◽  
Author(s):  
Citlalli Osorio-Yáñez ◽  
Julio C. Ayllon-Vergara ◽  
Laura Arreola-Mendoza ◽  
Guadalupe Aguilar-Madrid ◽  
Erika Hernández-Castellanos ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Systolic Function ◽  
Inorganic Arsenic ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Geometry

scholarly journals Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects

Circulation ◽  
2001 ◽  
Vol 103 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Vittorio Palmieri ◽  
Jonathan N. Bella ◽  
Donna K. Arnett ◽  
Jennifer E. Liu ◽  
Albert Oberman ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Systolic Function ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Geometry

Impact of age on left ventricular geometry and diastolic function in elderly patients with treated hypertension

2017 ◽  
Vol 26 (5) ◽  
pp. 264-271 ◽  
Author(s):  
Ayumi Toba ◽  
Taro Kariya ◽  
Rie Aoyama ◽  
Taizo Ishiyama ◽  
Yusuke Tsuboko ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Diastolic Function ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Geometry

scholarly journals Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial

2020 ◽  
pp. 204748732093921 ◽  
Author(s):  
Giovanni Cioffi ◽  
Carlo Bruno Giorda ◽  
Donata Lucci ◽  
Elisa Nada ◽  
Federica Ognibeni ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Systolic Function ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Systolic Function ◽  
Diabetes Therapy ◽  
Ventricular Geometry ◽  
Fractional Shortening

Aims To evaluate the effect of linagliptin on left ventricular systolic function beyond glycaemic control in type 2 diabetes mellitus. Methods and results A multicentre, randomised, double-blind, placebo controlled, parallel-group study, was performed (the DYDA 2 trial). Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function were randomly allocated in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their diabetes therapy. Eligibility criteria were age 40 years and older, haemoglobin A1c 8.0% or less (≤64 mmol/mol), no history of cardiac disease, concentric left ventricular geometry (relative wall thickness ≥0.42), impaired left ventricular systolic function defined as midwall fractional shortening 15% or less at baseline echocardiography. The primary end point was the modification of midwall fractional shortening over time. The main secondary objectives were changes in diastolic and/or in longitudinal left ventricular systolic function as measured by tissue Doppler echocardiography. One hundred and eighty-eight patients were enrolled, predominantly men with typical insulin-resistance comorbidities. At baseline, mean midwall fractional shortening was 13.3%±2.5. At final evaluation, 88 linagliptin patients and 86 placebo patients were compared: midwall fractional shortening increased from 13.29 to 13.82 (+4.1%) in the linagliptin group, from 13.58 to 13.84 in the placebo group (+1.8%, analysis of covariance P = 0.86), corresponding to a 2.3-fold higher increase in linagliptin than the placebo group, although non-statistically significant. Also, changes in diastolic and longitudinal left ventricular systolic function did not differ between the groups. Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. Conclusions In the DYDA 2 patients the addition of linagliptin to stable diabetes therapy was safe and provided a modest non-significant increase in left ventricular systolic function measured as midwall fractional shortening. Trial registration number: ClinicalTrial.gov (ID NCT02851745)

Sign in / Sign up

Export Citation Format

Share Document